BR112014013564A8 - composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz - Google Patents

composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz

Info

Publication number
BR112014013564A8
BR112014013564A8 BR112014013564A BR112014013564A BR112014013564A8 BR 112014013564 A8 BR112014013564 A8 BR 112014013564A8 BR 112014013564 A BR112014013564 A BR 112014013564A BR 112014013564 A BR112014013564 A BR 112014013564A BR 112014013564 A8 BR112014013564 A8 BR 112014013564A8
Authority
BR
Brazil
Prior art keywords
topical pharmaceutical
nose
ear
eye
pharmaceutical compositions
Prior art date
Application number
BR112014013564A
Other languages
English (en)
Other versions
BR112014013564A2 (pt
Inventor
Kumar Dhirendra
Avachat Makrand
Murali Narayanan
K Nagarajan Raja
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of BR112014013564A2 publication Critical patent/BR112014013564A2/pt
Publication of BR112014013564A8 publication Critical patent/BR112014013564A8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/10Expectorants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz a presente invenção proporciona composições farmacêuticas tópicas estáveis durante o armazenamento e estéreis, destinadas à aplicação ao olho, ouvido ou nariz, compreendendo dexametasona e ciprofloxacina. as composições farmacêuticas tópicas da invenção compreendem uma combinação de agente de tonicidade iônico e agente(s) de tonicidade não iônico(s). as composições farmacêuticas tópicas compreendem adicionalmente ácido bórico. a invenção proporciona um processo de preparação e esterilização das composições de modo a reduzir a quantidade de compostos relacionados e impurezas associadas às composições tópicas durante o armazenamento. as composições farmacêuticas tópicas da invenção observadas como sendo estáveis durante o armazenamento são fáceis de ressuspender. 1/1
BR112014013564A 2011-12-09 2012-12-07 composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz BR112014013564A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1534KO2011 2011-12-09
PCT/IB2012/057054 WO2013084194A1 (en) 2011-12-09 2012-12-07 Topical pharmaceutical compositions of anti-microbial agents and anti-inflammatory agents

Publications (2)

Publication Number Publication Date
BR112014013564A2 BR112014013564A2 (pt) 2017-06-13
BR112014013564A8 true BR112014013564A8 (pt) 2017-06-13

Family

ID=48573652

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014013564A BR112014013564A8 (pt) 2011-12-09 2012-12-07 composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz

Country Status (4)

Country Link
US (1) US20140315871A1 (pt)
BR (1) BR112014013564A8 (pt)
MX (1) MX2014006803A (pt)
WO (1) WO2013084194A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269616A1 (en) * 2015-12-07 2019-09-05 Emcure Pharmaceuticals Limited Sterile parenteral suspensions
CN113521001A (zh) * 2020-04-15 2021-10-22 江苏长泰药业有限公司 一种含地塞米松的混悬剂的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039146A1 (en) * 1995-06-06 1996-12-12 Bayer Corporation Non-irritation, non-sensitizing, non-ototoxic otic antibacterial compositions
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
US6066292A (en) * 1997-12-19 2000-05-23 Bayer Corporation Sterilization process for pharmaceutical suspensions
JP2003510263A (ja) * 1999-09-24 2003-03-18 アルコン,インコーポレイテッド シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
CN1887352A (zh) * 2006-07-13 2007-01-03 徐艳 治疗眼部真菌和细菌感染的组合物
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂

Also Published As

Publication number Publication date
US20140315871A1 (en) 2014-10-23
WO2013084194A1 (en) 2013-06-13
MX2014006803A (es) 2014-07-09
BR112014013564A2 (pt) 2017-06-13

Similar Documents

Publication Publication Date Title
CA2863964C (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
BR112015004984A2 (pt) formulações aquosas estáveis de adalimumab
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
BR112013022094A2 (pt) composições e métodos para o tratamento não cirúrgico da ptose
MY165124A (en) Semifluorinated alkane compositions
BR112015018838A2 (pt) estabilidade melhorada de novas composições líquidas
BR112018013104B8 (pt) Composição e método para crescimento de cabelos ou pelos
BR112014030820A2 (pt) formulação de anticorpos
CL2013003016A1 (es) Una composicion oftalmica topica para el tratamiento y/o la profilaxis de una infeccion producida por un microorganismo o un trastorno de al menos un tejido ocular, que comprende a) 0,01 a 10% de povidona yodada y b) un esteroide seleccionado de acetato de prednisolona, etabonato de loteprednol, difluprednato, entre otros, o bromfenaco.
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
BR112014004687A2 (pt) imidazopiridazinas amino-substituídas
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112012030959A2 (pt) emulsões acrílicas intumescíveis em álcali que compreendem ácido acrílico, seu uso em formulações aquosas e formulações que contenham as mesmas
BR112015002372A2 (pt) composições e métodos para a redução do teor de álcool no sangue
BR112015001313A2 (pt) composições de vacina
BR112016014247A2 (pt) Composição aquosa esterilizada, processos de fabricação da mesma, de obtenção de uma composição aquosa esterilizada de ácido hialurônico, utilizações de mepivacaína, e de uma composição aquosa esterilizada, kit, e, processo para melhorar a resistência à degradação das propriedades reológicas de uma composição aquosa injetável de ácido hialurônico
BR112015002464B8 (pt) processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona
BR112014027047A2 (pt) nova formulação
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
BR112014027582A8 (pt) composições oftalmicas com proteção e retenção de dessecação aperfeiçoada
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112012018154A2 (pt) agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular
BR112015006464A2 (pt) composição farmacêutica compreendendo rebamipida
BR112014013564A8 (pt) composição farmacêutica tópica destinada à aplicação ao olho, ouvido ou nariz

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]